|
| |
CCR5
Gene Information from Publications |
| Publication Link |
Summary of findings |
| 18197127 |
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) |
| 18205260 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18255039 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18311470 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18361062 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17426779 |
In this review we focus on the known polymorphisms of two chemokines: CCL2, CCL5 and their corresponding receptors (CCR2, CCR5) and we also discuss their associations with susceptibility and progression to selected immune-mediated diseases. [REVIEW] |
| 16314800 |
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) |
| 15331395 |
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) |
| 10985308 |
Observational study of gene-disease association. (HuGE Navigator) |
| 11023492 |
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | →View more information from publications. |
Recent Publications on CCR5: |  |
Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.
In this report, we show that affinity purified human anti-delta opioid... | 3rd November, 2009
| Department of Immunobiology, University of Arizona, 1656 E. Mabel Street,
| J Neuroimmunol. 2009 Oct 29.
DOI Direct Link |
In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20).
Objectives To block the different mechanisms of HIV mucosal transmission,... | 31st October, 2009
| Universite Paris Descartes (Paris V), and Laboratoire de Virologie,
| J Antimicrob Chemother. 2009 Oct 29.
DOI Direct Link |
Common CCR 5 polymorphism in stroke: the CCR 5 delta32 polymorphism differentiates cardioembolism from other aetiologies of ischaemic cerebrovascular diseases.
Inflammation is involved in the development of atherosclerosis. The CC... | 31st October, 2009
| Department of Neurology, Neuro-Angiological Research Center, Karolinska
| Scand J Immunol. 2009 Nov;70(5):475-80.
DOI Direct Link |
Response to Vicriviroc in Treatment-Experienced Subjects, as Determined by an Enhanced-Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211.
The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to... | 31st October, 2009
| Harvard School of Public Health, 2Brigham and Women's Hospital, Harvard
| J Infect Dis. 2009 Oct 29.
DOI Direct Link |
Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7.
BACKGROUND:: The Step Study was a randomized trial to reduce HIV infection... | 30th October, 2009
| aCR UK Centre, School of Cancer Sciences, UK bSchool of Immunity and
| AIDS. 2009 Oct 27.
DOI Direct Link |
→View more research publications. |
Press Releases on CCR5:
|
 |
| Sangamo BioSciences Research Collaborators Awarded Grant From California Institute for Regenerative Medicine to Develop Zinc Finger Nuclease-Based Stem Cell Therapy for HIV/AIDS |
28th October, 2009 |
Sangamo BioSciences, Inc. |
RICHMOND, Calif. Oct. 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the California Institute for Regenerative Medicine (CIRM) has
|
| Schering-Plough Reports Financial Results for 2009 Third Quarter |
22nd October, 2009 |
Schering-Plough Corporation |
-- New product launches in Japan, the world's second largest pharmaceutical
market, including ASMANEX (mometasone furoate) for asthma and REMERON
(mirtazapine) for major
|
| New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance |
12th June, 2009 |
Quest Diagnostics Incorporated |
Faster reporting aids physicians in identifying HIV mutations that can inhibit effectiveness of newest class of antiretroviral therapy
MADISON, N.J., June 12 /PRNewswire-FirstCall/ -
|
| Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013 |
19th May, 2009 |
Decision Resources |
By 2018, Gilead's Quad Will Become the Highest-Selling Antiretroviral in the World's Major Markets, According to a New Report from Decision Resources
|
| Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research |
4th May, 2009 |
Sangamo BioSciences, Inc. |
RICHMOND, Calif., May 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), the world leader in the research and development of zinc finger DNA-binding proteins (ZFPs),
|
CCR5 results (if any) from reagent suppliers | 
|
Search Bioportfolio and other Life Science Sites for CCR5,
or search for CCR5 on BioPortfolio's antibody search engine.
This page has been viewed 497 times
Recent Search Terms used to find this page: chemokine drug and market | anti ccr5 gene therapy | ccr5 zinc finger November 2009 | CCR5 chemokine C-C motif receptor 5 Homo sapiens gene delected | CCR5 motif | Rheumatoid arthritis Chemokine receptor 5 | HIV drug discovery 2009 CCR5 | mouse anti-human ccr5 antibody | chemokine receptors therapy market | .
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
